AXIM BIOTECHNOLOGIES, INC.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $39.5K | $8.9K | $60.5K | $0 | $799.5K | $195.6K | $47.6K |
| Cost of Revenue | — | — | — | — | $0 | $0 | $8.5K | $42.9K |
| Gross Profit | — | — | — | — | $0 | $0 | $187.1K | $4.7K |
| Gross Margin | — | — | — | — | — | 0.0% | 95.6% | 9.9% |
| Operating Expenses | ||||||||
| Research & Development | — | $125.5K | $153.7K | $284.9K | $426.7K | $0 | $2.1M | $1.4M |
| SG&A Expense | — | $2.2M | $4.1M | $5.7M | $4.5M | $3.1M | $3.2M | $1.8M |
| Operating Income | — | $-2.8M | $-4.7M | $-14.0M | $-4.9M | $-3.1M | $-5.0M | $-3.1M |
| Operating Margin | — | -6,961.0% | -52,425.6% | -23,114.5% | — | -388.9% | -2,574.5% | -6,619.5% |
| Interest Expense | — | $140.0K | $261.5K | $247.8K | $234.8K | $222.2K | $456.1K | $315.0K |
| Pretax Income | — | $-8.1M | $-6.2M | $-16.0M | $-6.3M | $-3.0M | $-6.8M | $-4.2M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-8.1M | $-6.2M | $-16.0M | $-6.4M | $-6.4M | $-6.8M | $-4.2M |
| Net Margin | — | -20,395.0% | -70,343.1% | -26,517.2% | — | -806.5% | -3,453.0% | -8,761.7% |
| EPS (Basic) | — | $-0.04 | $-0.04 | $0.12 | $-0.06 | $-0.10 | $-0.12 | $-0.08 |
| EPS (Diluted) | — | $-0.04 | $-0.04 | $0.12 | $-0.06 | $-0.10 | $-0.12 | $-0.08 |
| Shares Outstanding (Basic) | 278.4M | 245.9M | 192.4M | 138.1M | 125.3M | 64.9M | 59.6M | 54.6M |
| Shares Outstanding (Diluted) | 278.4M | 245.9M | 192.4M | 138.1M | 125.3M | 64.9M | 59.6M | 54.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |